GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Cash Conversion Cycle

aTyr Pharma (aTyr Pharma) Cash Conversion Cycle

: 0.00 (As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

aTyr Pharma's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.
aTyr Pharma's Days Inventory for the three months ended in Dec. 2023 was .
aTyr Pharma's Days Payable for the three months ended in Dec. 2023 was .
Therefore, aTyr Pharma's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 0.00.


aTyr Pharma Cash Conversion Cycle Historical Data

The historical data trend for aTyr Pharma's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

aTyr Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, aTyr Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma Cash Conversion Cycle Distribution

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Cash Conversion Cycle falls into.



aTyr Pharma Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

aTyr Pharma's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+-
=0.00

aTyr Pharma's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


aTyr Pharma  (NAS:LIFE) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


aTyr Pharma Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma (aTyr Pharma) Business Description

Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
Sanjay Shukla officer: Chief Medical Officer C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot officer: Chief Financial Officer 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke director C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p. 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah officer: Vice President, Manufacturing C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake officer: Vice President, Finance C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King officer: See Remarks 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121

aTyr Pharma (aTyr Pharma) Headlines

From GuruFocus

aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment

By Value_Insider Value_Insider 12-15-2022

aTyr Pharma to Present at Upcoming Investor Conferences

By Value_Insider Value_Insider 11-10-2022